April 20, 2024 16:09 (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Love jihad is spreading: Karnataka Congress corporator, whose daughter was killed, contradicts Siddaramaiah's claims | Karnataka Congress corporator's daughter killed; CM Siddaramaiah cites 'personal reasons' | Elon Musk postpones upcoming visit to India: Reports | 'Had mangoes only three thrice, sweets 6 times in jail': Arvind Kejriwal counters ED claims in court | 'Opposition got donations through bonds, is that extortion as well?' Amit Shah slams Rahul Gandhi
CCI approves merger of Serum Institute subsidiaries Biocon Biologics and CTPL Serum Institute

CCI approves merger of Serum Institute subsidiaries Biocon Biologics and CTPL

India Blooms News Service | @indiablooms | 19 May 2022, 06:39 pm

New Delhi: The Competition Commission of India (CCI) has approved the merger by absorption of Covidshield Technologies into Biocon Biologics in consideration for the acquisition of approximately 15 percent equity shareholding of Biocon Biologics by Serum Institute Life Sciences.

The Proposed Combination involves a merger by absorption of Covidshield Technologies Private Limited (CTPL), a wholly-owned subsidiary of the Serum Institute Life Sciences Private Limited (Acquirer) into the Biocon Biologics Limited (Target) pursuant to a scheme of the merger in consideration of which the Acquirer will acquire approximately 15 percent equity shareholding on a fully diluted basis in the Target, CCI said in a statement on Thursday.

The acquirer is a subsidiary of Serum Institute of India Private Limited and was established as a company for further development and commercialization of vaccines and therapies against COVID-19, the anti-trust watchdog stated.

It also had plans to further develop vaccines against other infectious diseases.

At present, the acquirer is in the process of setting up its own manufacturing facility.

CTPL is a wholly-owned subsidiary of the acquirer, which shall be merged into the Target pursuant to the Proposed Transaction.

It was incorporated to undertake the business of marketing, selling, and distributing vaccines, drugs and other pharmaceutical products.

The Target is a subsidiary of Biocon Limited, and it offers treatment for chronic and acute diseases such as diabetes, oncology, nephrology, cancer, and autoimmune diseases.

The Target also has research and development centres in Bengaluru and Chennai.

It has manufacturing facilities in Bengaluru and Malaysia for monoclonal antibodies, recombinant proteins and insulins.

Detailed order of the CCI will follow.
 

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.